Across TCGA pan-cancer cohorts, HNRNPCP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HNRNPCP2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher HNRNPCP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HNRNPCP2 expression acts as an unfavorable survival marker.

CESC, BLCA, and UCEC are the cancer types where HNRNPCP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.227	0.798	.047	6	view →
BLCA	DFS	Median	All	0.153	0.615	.024	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.016	0.454	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: HNRNPCP2 tumor-vs-normal RNA expression · all HNRNPCP2 data types